Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The tremendous clinical and etiological variability between individuals with autism spectrum disorder (ASD) has made precision medicine the most promising treatment approach. It aims to combine new pathophysiologically based treatments with objective tests (stratification biomarkers) to predict which treatment may be beneficial for a particular person. Here we discuss significant advances and current challenges for this approach: rare monogenic forms of ASD have provided a major breakthrough for the identification of treatment targets by providing a means to trace causal links from a gene to specific molecular alterations and biological pathways. To estimate whether treatment targets thus identified may be useful for larger patient groups we need a better understanding of whether different etiologies (i.e., genetic and environmental risk factors acting at different critical time points) lead to convergent or divergent molecular mechanisms, and how they map onto differences in circuit-level brain and cognitive development, and behavioral symptom profiles. Several recently failed clinical trials with syndromic forms of ASD provide valuable insights into conceptual and methodological issues linked to limitations in the translatability from animal models to humans, placebo effects, and a need for mechanistically plausible, objective outcome measures. To identify stratification biomarkers that enrich participant selection in clinical trials, large-scale multi-modal longitudinal observational studies are underway. Addressing these different factors in the next generation of research studies requires a translatable developmental perspective and multidisciplinary, collaborative efforts, with a commitment to sharing protocols and data, to increase transparency and reproducibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067
Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318179964f · Cited by 3,399 · cited 1×
“In addition, up to 70% of individuals have one or more psychiatric and/or medical comorbidities, such as intellectual disability, ADHD, irritability, aggression, anxiety, depression, epilepsy, and sleep anomalies (4).”
BackgroundDi Martino, A., Yan, C.-G., Li, Q., Denio, E., Castellanos, F. X., Alaerts, K., Anderson, J. S., Assaf, M., Bookheimer, S. Y., Dapretto, M., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.78 · Cited by 2,780
Model of autism: increased ratio of excitation/inhibition in key neural systems
Rubenstein, J. L. R., & Merzenich, M. M. (2003) · Genes, Brain and Behavior · doi:10.1034/j.1601-183x.2003.00037.x · Cited by 2,768 · cited 1×
“For example, abnormalities in synapse development, function, and plasticity may broadly impact the balance between excitation (mainly modulated by glutamate) and inhibition (mainly modulated by gamma-aminobutyric acid, GABA) In particular, it has been suggested that (some forms of) ASD may be linked to disproportional…”
BackgroundBaird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D., & Charman, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69041-7 · Cited by 2,104
Spatio-temporal transcriptome of the human brain
Kang, H. J., Kawasawa, Y. I., Cheng, F., Zhu, Y., Xu, X., Li, M., Sousa, A. M. M., Pletikos, M., Meyer, K. A., Sedmak, G., et al. (2011) · Nature · doi:10.1038/nature10523 · Cited by 2,084 · cited 2×
“Brain development is initially determined by distinct temporal and spatial stages of gene expression (25) and intrinsic neuronal activity (26) but then becomes actively refined by interactions with the environment.”
BackgroundGenetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism
Hallmayer, J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.76 · Cited by 1,970 · cited 1×
“For instance, human studies comparing monozygotic and dizygotic twins have consistently revealed significant environmental influences that account for approximately 5–6% (23) of the observed variance in ASD.”
BackgroundTranscriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology
Voineagu, I., Wang, X., Johnston, P., Lowe, J. K., Tian, Y., Horvath, S., Mill, J., Cantor, R. M., Blencowe, B. J., & Geschwind, D. H. (2011) · Nature · doi:10.1038/nature10110 · Cited by 1,874
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“Animal models of syndromic and monogenic forms showed significant pre-clinical promise such that several molecular aberrations and behavioral phenotypes could be reversed through pharamacological treatment or genetic rescue – sometimes even in adulthood (15, 16).”
BackgroundSex/Gender Differences and Autism: Setting the Scene for Future Research
Lai, M.-C., Lombardo, M. V., Auyeung, B., Chakrabarti, B., & Baron-Cohen, S. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.10.003 · Cited by 1,120
From the genetic architecture to synaptic plasticity in autism spectrum disorder
Bourgeron, T. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3992 · Cited by 975 · cited 4×
“The rare genetic mutation may still have some penetrance, but the effect may be “milder,” including sub-threshold clinical symptoms (10).”
BackgroundInfluentialA Systematic Review of Early Intensive Intervention for Autism Spectrum Disorders
Warren, Z., McPheeters, M. L., Sathe, N., Foss-Feig, J. H., Glasser, A., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0426 · Cited by 790
Understanding heterogeneity in clinical cohorts using normative models: Beyond case-control studies
Marquand, A. F., Rezek, I., Buitelaar, J., & Beckmann, C. F. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.023 · Cited by 683 · cited 1×
“To do this, hierarchical clustering methods (47) or normative modeling approaches to neuroimaging data (48), have recently been used.”
MethodJacquemont, S., Coe, B. P., Hersch, M., Duyzend, M. H., Krumm, N., Bergmann, S., Beckmann, J. S., Rosenfeld, J. A., & Eichler, E. E. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.02.001 · Cited by 605
Howlin, P. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1022270118899 · Cited by 563
Maternal infection and immune involvement in autism
Patterson, P. H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.03.001 · Cited by 520
Neural Plasticity: The Effects of Environment on the Development of the Cerebral Cortex
Huttenlocher, P. R. (2002) · doi:10.4159/9780674038936 · Cited by 421
Guiding Neuronal Cell Migrations
Marin, O., Valiente, M., Ge, X., & Tsai, L.-H. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001834 · Cited by 417 · cited 1×
“Brain development is initially determined by distinct temporal and spatial stages of gene expression (25) and intrinsic neuronal activity (26) but then becomes actively refined by interactions with the environment.”
BackgroundSix Developmental Trajectories Characterize Children With Autism
Fountain, C., Winter, A. S., & Bearman, P. S. (2012) · Pediatrics · doi:10.1542/peds.2011-1601 · Cited by 372
Key role for gene dosage and synaptic homeostasis in autism spectrum disorders
Toro, R., Konyukh, M., Delorme, R., Leblond, C., Chaste, P., Fauchereau, F., Coleman, M., Leboyer, M., Gillberg, C., & Bourgeron, T. (2010) · Trends in Genetics · doi:10.1016/j.tig.2010.05.007 · Cited by 331 · cited 1×
“Brain networks may also differ in their resilience to gene dosage such that the functional effects of abnormal gene dosage could be localized even if the genetic abnormalities are widespread (30).”
BackgroundReduced GABAergic Action in the Autistic Brain
Robertson, C. E., Ratai, E.-M., & Kanwisher, N. (2016) · Current Biology · doi:10.1016/j.cub.2015.11.019 · Cited by 327
Autism: A “Critical Period” Disorder?
LeBlanc, J. J., & Fagiolini, M. (2011) · Neural Plasticity · doi:10.1155/2011/921680 · Cited by 301 · cited 1×
“However, this approach makes the strong assumption that anomalies in circuits underpinning sensory anomalies are “primary deficits” in autism (37, 38) with down-stream effects on networks supporting higher level (and later developing) cognitive and social-cognitive functions – a premise that remains to be further test…”
BackgroundBerry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270
The emerging role of SHANK genes in neuropsychiatric disorders
Guilmatre, A., Huguet, G., Delorme, R., & Bourgeron, T. (2014) · Developmental Neurobiology · doi:10.1002/dneu.22128 · Cited by 237
Connecting Genes to Brain in the Autism Spectrum Disorders
Abrahams, B. S., & Geschwind, D. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.47 · Cited by 193 · cited 1×
“Changes in synaptic function and timing might then particularly disrupt the connectivity of higher order association areas, including frontal–parietal, frontal–temporal, and frontal–striatal circuits (32).”
BackgroundIdentification and validation of biomarkers for autism spectrum disorders
Loth, E., Spooren, W., Ham, L. M., Isaac, M. B., Auriche-Benichou, C., Banaschewski, T., Baron-Cohen, S., Broich, K., Bölte, S., Bourgeron, T., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.7 · Cited by 140 · cited 3×
“Large-scale multi-center multidisciplinary observational studies, such as the EU-AIMS Longitudinal European Autism Project (LEAP) are currently underway that have sufficient power to identify stratification markers (44).”
BackgroundSelf-citationSpooren, W., Lindemann, L., Ghosh, A., & Santarelli, L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.004 · Cited by 119 · cited 4×
“Is autism, at least in part, a disorder of fetal programming? Arch Gen Psychiatry (2011) 68(11):1091–2.”
BackgroundInfluentialSelf-citationMasi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78 · cited 1×
“The effect size of the placebo response in medication trials for ASD is estimated to be “moderate” (41).”
Background
Cited by
Big data approaches to decomposing heterogeneity across the autism spectrum
Lombardo, M. V., Lai, M.-C., & Baron-Cohen, S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0321-0 · Cited by 537
Russell, G., Mandy, W., Elliott, D., White, R., Pittwood, T., & Ford, T. (2019) · Molecular Autism · doi:10.1186/s13229-019-0260-x · Cited by 366
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
Self-citationAltered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets
Postema, M. C., van Rooij, D., Anagnostou, E., Arango, C., Auzias, G., Behrmann, M., Filho, G. B., Calderoni, S., Calvo, R., Daly, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13005-8 · Cited by 267
Self-citationNeurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance
Bozzi, Y., Provenzano, G., & Casarosa, S. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13595 · Cited by 250
Metadata
- Authors
- Loth, E., Murphy, D. G., & Spooren, W.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2016-11-29
- Volume
- 7
- Pages
- 188-188
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2557554686
- Cited by
- 86
- References
- 28
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.